Laxatives & Antidiarrheals — Laxatives and antidiarrheals overview - Pharmacology

SECTION 1

Historical Context & Motivation

The management of disordered bowel function is among the oldest concerns in medical practice. Ancient civilizations recognized that both constipation and diarrhea could threaten health and survival, and early practitioners developed a rich pharmacopoeia of plant-derived remedies long before the mechanisms of gastrointestinal motility were understood. The concept of catharsis—purging the bowels to restore health—was a central pillar of Hippocratic and Galenic medicine, influencing clinical practice for nearly two millennia. As pharmacology matured into a modern science, researchers began to classify these agents by mechanism, leading to the rational drug selection strategies we employ today.

~1550 BCE • Ebers Papyrus

Ancient Egyptian medical texts describe the use of castor oil and senna preparations as purgatives, establishing the earliest documented pharmacotherapy for constipation.

1906 • Phenolphthalein Introduced

Originally a pH indicator dye, phenolphthalein was discovered to have stimulant laxative properties and became one of the first synthetic laxatives widely used in clinical medicine.

1953 • Loperamide & Opioid Antidiarrheals

Research into opioid-receptor pharmacology led to the development of peripherally acting μ-opioid receptor agonists like diphenoxylate and later loperamide, which inhibit peristalsis without significant CNS effects at therapeutic doses.

2000s • Chloride Channel & Secretory Agents

The FDA approved lubiprostone (2006) and linaclotide (2012), representing a new mechanistic class of prosecretory agents that target intestinal chloride channels and guanylate cyclase-C receptors, respectively.

Despite millennia of use, the fundamental clinical question remains the same: how do we restore normal bowel function—whether the problem is insufficient motility and fluid secretion (constipation) or excessive motility and secretion (diarrhea)—using agents that are safe, effective, and mechanistically appropriate for the underlying etiology? Understanding the pharmacological classifications of laxatives and antidiarrheals is the foundation for answering this question rationally.

SECTION 2

Core Principles & Definitions

Normal defecation depends on a coordinated interplay among intestinal motility, luminal fluid balance, mucosal absorption, and the enteric nervous system. Laxatives are pharmacological agents that promote bowel evacuation by increasing stool water content, stimulating peristalsis, or both. Conversely, antidiarrheals reduce stool frequency and volume by decreasing intestinal motility, enhancing absorption, or modifying secretory activity. A clinician's ability to select the appropriate agent hinges on understanding five foundational principles.

Osmotic Gradient

Non-absorbable or poorly absorbed solutes draw water into the intestinal lumen by osmosis, softening stool and distending the bowel wall to trigger reflex peristalsis. This principle underlies osmotic laxatives such as polyethylene glycol and lactulose.

Mucosal Stimulation

Certain agents directly stimulate the myenteric plexus (Auerbach's plexus) of the colon, increasing propulsive contractions and inhibiting water reabsorption. Bisacodyl and senna (sennosides) are classic examples of stimulant laxatives.

Luminal Bulking

Hydrophilic colloids such as psyllium and methylcellulose absorb water to form a gel, increasing fecal mass and distending the colon to activate stretch receptors and the defecation reflex.

Opioid Receptor Modulation

Activation of μ-opioid receptors on enteric neurons decreases acetylcholine release, slowing peristalsis and increasing segmental (non-propulsive) contractions. This mechanism is exploited by antidiarrheal agents like loperamide.

Secretory Modulation

Agents such as bismuth subsalicylate reduce prostaglandin-mediated chloride secretion, while prosecretory agents like lubiprostone activate ClC-2 chloride channels to increase luminal fluid. Both sides of this principle are clinically important.

✦

KEY TAKEAWAY

Think of the intestinal lumen as a river. Laxatives either add more water to the river (osmotic agents), make the riverbed more slippery (stool softeners), speed up the current (stimulants), or widen the channel with debris (bulk formers). Antidiarrheals do the opposite—they dam the river (opioid agents), absorb the overflow (adsorbents), or shut off tributaries feeding into it (antisecretory agents). Selecting the right drug means diagnosing which part of the river's flow needs correction.

SECTION 3

Visual Overview — Laxative & Antidiarrheal Mechanism Map

The mechanism map divides agents into laxative classes (left) and antidiarrheal classes (right). Despite their opposing clinical effects, both categories ultimately modulate luminal water content and intestinal motility—they simply push in opposite directions.

The diagram above illustrates that laxatives and antidiarrheals are not pharmacological opposites in the simplistic sense of being agonist–antagonist pairs at the same receptor. Instead, they represent a diverse collection of mechanisms that converge on a common physiological endpoint: the net volume of fluid within the intestinal lumen and the propulsive efficiency of peristalsis. Bulk-forming and osmotic laxatives increase luminal water through physical and osmotic mechanisms, respectively, while stimulant laxatives act neuronally to enhance propulsive contractions. On the antidiarrheal side, μ-opioid agonists like loperamide reduce motility, adsorbents like bismuth subsalicylate physically bind toxins and reduce secretion, and bile acid binders such as cholestyramine sequester bile salts that would otherwise stimulate colonic secretion.

SECTION 4

Mechanisms of Action — Deep Dive

Laxative Mechanisms

Bulk-forming laxatives are hydrophilic, largely non-digestible polysaccharides (e.g., psyllium, methylcellulose, polycarbophil) that swell in the presence of water, increasing fecal mass. This distension activates mechanoreceptors in the colonic wall, triggering the peristaltic reflex via intrinsic enteric neural circuits. Adequate fluid intake is essential; without it, these agents can paradoxically cause obstruction. Onset is typically 12–72 hours, making them best suited for chronic management rather than acute relief.

Osmotic laxatives rely on the principle that water follows solute. Polyethylene glycol (PEG 3350) is an inert, non-absorbable polymer that retains water isosmotically in the lumen. Lactulose, a synthetic disaccharide undigested by human enzymes, is fermented by colonic bacteria to short-chain fatty acids and lactic acid, which lower intraluminal pH and generate an osmotic gradient. Saline osmotic agents such as magnesium hydroxide (Mg(OH)₂) and magnesium citrate deliver poorly absorbed cations that exert a powerful osmotic effect, and may also stimulate cholecystokinin (CCK) release, further promoting motility.

Stimulant laxatives such as bisacodyl and sennosides act primarily on the submucosal (Meissner's) and myenteric (Auerbach's) plexuses, stimulating secretion of water and electrolytes into the lumen while simultaneously increasing propulsive contractions. Sennosides are prodrugs activated by bacterial β-glucosidases in the colon to their active aglycone, rheinanthrone. Chronic use has historically raised concern for melanosis coli (harmless pigment deposition) and putative neuronal damage, though recent evidence suggests the risk of cathartic colon syndrome has been overstated.

Stool softeners (emollients) like docusate sodium are anionic surfactants that lower the surface tension at the oil–water interface within stool, allowing water and lipids to penetrate the fecal mass. Although widely prescribed, evidence for their efficacy in chronic constipation is relatively modest; they are most useful for patients who need to avoid straining, such as those recovering from surgery or myocardial infarction.

Prosecretory agents represent the newest mechanistic class. Lubiprostone is a bicyclic fatty acid derived from prostaglandin E₁ that activates type-2 chloride channels (ClC-2) on the apical membrane of intestinal epithelial cells, promoting Cl⁻ secretion followed by paracellular sodium and water movement into the lumen. Linaclotide and plecanatide are guanylate cyclase-C (GC-C) agonists that increase intracellular cGMP, activating the CFTR chloride channel and inhibiting the NHE3 sodium-hydrogen exchanger, producing both a secretory and an analgesic (visceral pain-reducing) effect relevant to irritable bowel syndrome with constipation (IBS-C).

Antidiarrheal Mechanisms

Opioid-receptor agonists are the mainstay of symptomatic antidiarrheal therapy. Loperamide binds μ-opioid receptors on the myenteric plexus, decreasing acetylcholine release and thereby reducing propulsive peristalsis while increasing segmental (mixing) contractions and anal sphincter tone. Critically, loperamide is a substrate for the efflux transporter P-glycoprotein (P-gp) at the blood–brain barrier, which limits CNS penetration at therapeutic doses. Diphenoxylate, co-formulated with subtherapeutic atropine to discourage abuse, has similar peripheral effects but is a Schedule V controlled substance due to modest CNS penetration at supratherapeutic doses.

Bismuth subsalicylate exerts multiple mechanisms: it inhibits prostaglandin and chloride secretion (antisecretory effect), has mild antimicrobial action against enterotoxigenic bacteria, and physically coats the intestinal mucosa (adsorbent/protective effect). This multifaceted profile makes it particularly useful for traveler's diarrhea. Patients should be counseled about harmless darkening of the stool and tongue. Crofelemer is a botanically derived antisecretory agent that inhibits both CFTR and calcium-activated chloride channels (CaCC) on the luminal side of enterocytes, reducing chloride—and therefore water—secretion. It is FDA-approved specifically for HIV/AIDS-associated diarrhea in patients on antiretroviral therapy.

This enterocyte cross-section highlights the key molecular targets: ClC-2 channels (activated by lubiprostone), GC-C/CFTR (activated by linaclotide), and CFTR/CaCC inhibition (by crofelemer). The net direction of chloride and water movement determines whether the clinical effect is laxation or antidiarrheal.

SECTION 5

Detailed Drug Classification & Comparison

Laxative Classification Table

Class	Prototype Drug(s)	Mechanism	Onset	Key Adverse Effects
Bulk-forming	Psyllium, methylcellulose, polycarbophil	Absorb water → ↑ fecal mass → distension activates peristaltic reflex	12–72 h	Bloating, flatulence; obstruction if taken without adequate fluid
Osmotic	PEG 3350, lactulose, magnesium hydroxide, magnesium citrate	Non-absorbable solutes retain/draw H₂O into lumen by osmosis	24–48 h (PEG); 0.5–6 h (Mg salts)	Electrolyte imbalance (hypermagnesemia in renal impairment); cramping
Stimulant	Bisacodyl, senna (sennosides)	Activate myenteric plexus → ↑ propulsive motility; inhibit water reabsorption	6–12 h (oral); 15–60 min (rectal)	Abdominal cramps, melanosis coli; electrolyte depletion with chronic use
Stool softener	Docusate sodium, docusate calcium	Surfactant → ↓ surface tension → H₂O & fat penetrate stool	24–72 h	Mild cramping; limited efficacy as monotherapy
Prosecretory	Lubiprostone, linaclotide, plecanatide	Activate Cl⁻ channels (ClC-2) or GC-C → ↑ intestinal fluid secretion	24–48 h	Nausea (lubiprostone); diarrhea (linaclotide); teratogenic risk—CI in pregnancy
Lubricant	Mineral oil	Coats stool with hydrophobic layer → ↓ water reabsorption, eases passage	6–8 h	Lipoid pneumonia (aspiration risk); malabsorption of fat-soluble vitamins (A, D, E, K)

Major classes of laxatives with prototypes, mechanisms, onset, and adverse effects

Antidiarrheal Classification Table

Class	Prototype Drug(s)	Mechanism	Key Considerations
Opioid agonist (antimotility)	Loperamide, diphenoxylate/atropine	μ-opioid receptor activation → ↓ ACh release → ↓ peristalsis, ↑ segmental contractions, ↑ anal sphincter tone	Avoid in dysentery/bloody diarrhea (risk of toxic megacolon); loperamide P-gp substrate limits CNS entry; diphenoxylate—Schedule V
Adsorbent / protective	Bismuth subsalicylate	Adsorbs toxins; ↓ PG-mediated Cl⁻ secretion; mild antimicrobial effect	Black stool/tongue (harmless); avoid with aspirin allergy or in children (Reye syndrome risk from salicylate component)
Antisecretory	Crofelemer	Inhibits CFTR and CaCC Cl⁻ channels on luminal membrane → ↓ Cl⁻ and H₂O secretion	FDA-approved only for HIV-associated diarrhea on ART; does not inhibit pathogen clearance
Bile acid sequestrant	Cholestyramine (off-label)	Binds bile acids in lumen → prevents bile-salt-induced colonic secretion	Useful in bile acid malabsorption diarrhea (post-cholecystectomy, ileal resection); may bind other drugs

Major classes of antidiarrheals with prototypes, mechanisms, and clinical considerations

⚠

Clinical Pearl

In acute infectious diarrhea with fever or bloody stools (dysentery), antimotility agents like loperamide should generally be avoided because slowing gut transit can delay pathogen clearance and increase the risk of toxic megacolon, hemolytic-uremic syndrome (in EHEC), or prolonged bacteremia. Oral rehydration therapy (ORT) remains the cornerstone of management.

SECTION 6

Worked Clinical Example

Consider the following clinical scenario: A 68-year-old woman with chronic kidney disease (CKD stage 3b, eGFR 38 mL/min/1.73 m²) presents with chronic constipation. She is on chronic opioid therapy for osteoarthritis pain. The clinician must select an appropriate laxative while avoiding agents that could cause electrolyte imbalances in the setting of impaired renal function.

Selecting a Laxative for a Patient with CKD and Opioid-Induced Constipation

1
Step 1 — Identify the Etiology of Constipation

This patient's constipation is likely opioid-induced constipation (OIC). Opioids activate μ-receptors on enteric neurons, reducing propulsive peristalsis and increasing water absorption from stool. The patient's age and possible reduced fluid intake may be contributing factors as well.

Primary etiology: Opioid-induced constipation (OIC)
2
Step 2 — Eliminate Contraindicated Agents

Magnesium-containing osmotic laxatives (Mg(OH)₂, magnesium citrate) are contraindicated in patients with significant renal impairment because the kidneys cannot adequately excrete magnesium, leading to risk of hypermagnesemia (muscle weakness, hypotension, cardiac arrest at extreme levels). Sodium phosphate preparations are similarly risky due to hyperphosphatemia and acute phosphate nephropathy. Mineral oil should be used cautiously given aspiration risk in elderly patients.

Eliminated: Mg-based osmotics, sodium phosphate, mineral oil
3
Step 3 — Consider First-Line Options

PEG 3350 (MiraLAX) is an excellent first-line osmotic laxative in CKD because it is an inert polymer that does not introduce absorbable electrolytes. It is non-fermentable (less bloating than lactulose) and has a predictable dose–response relationship. A bulk-forming agent like psyllium can be added if the patient can maintain adequate hydration. For the opioid-specific component, if conventional laxatives fail, a peripherally acting μ-opioid receptor antagonist (PAMORA) such as methylnaltrexone or naloxegol could be considered, as these agents selectively block peripheral opioid receptors without reversing central analgesia.

First-line recommendation: PEG 3350 ± psyllium; escalate to PAMORA if refractory
4
Step 4 — Formulate a Monitoring Plan

Monitor stool frequency and consistency using the Bristol Stool Scale (target: type 3–4). Reassess electrolytes (especially K⁺, Mg²⁺, and phosphate) periodically given CKD. Ensure the patient is counseled on adequate fluid intake (≥ 1.5 L/day unless fluid-restricted). If escalation to a stimulant laxative (bisacodyl or senna) is needed for rescue, use intermittently to avoid electrolyte depletion and potential dependence.

Monitor: Bristol Stool Scale, electrolytes, fluid intake; use stimulant PRN only

SECTION 7

Strengths, Limitations & Clinical Comparisons

Factor	Laxatives	Antidiarrheals
Therapeutic goal	Restore regular bowel movements; relieve straining and discomfort	Reduce stool frequency and volume; prevent dehydration
Key strength	Multiple mechanistic classes allow tailoring to etiology; many are OTC, inexpensive, and well-tolerated	Rapid symptom relief (loperamide works within 1–3 h); critical for fluid loss prevention
Key limitation	Chronic stimulant use can cause electrolyte imbalance; osmotic agents may cause bloating; prosecretory agents are expensive	Antimotility agents may worsen invasive infections; loperamide abuse (high-dose for euphoria) can cause fatal cardiac arrhythmias (QT prolongation)
When to avoid	Suspected bowel obstruction, acute surgical abdomen, fecal impaction (except for specific disimpaction protocols)	Dysentery (bloody diarrhea with fever), C. difficile infection (risk of toxic megacolon), pediatric settings without physician guidance
Adjunct therapy	Dietary fiber, adequate hydration, physical activity, biofeedback for dyssynergic defecation	Oral rehydration solution (ORS), probiotics (strain-specific evidence), zinc supplementation in pediatric populations

Comparative overview of laxative and antidiarrheal pharmacotherapy

✦

KEY TAKEAWAY

In clinical practice, the choice between—and within—laxative and antidiarrheal classes is never one-size-fits-all. A helpful framework is the "mechanism–etiology match" principle: identify whether the primary problem is motility, secretion, absorption, or a combination, then select the agent whose mechanism most directly addresses that pathophysiology. Just as an engineer selects a specific tool for a specific type of structural failure, the pharmacist or prescriber should match the drug class to the physiological derangement.

SECTION 8

Connection to Advanced GI Pharmacotherapy

The foundational pharmacology of laxatives and antidiarrheals connects directly to several advanced therapeutic domains. Understanding these connections prepares students for more specialized coursework in clinical pharmacology and gastroenterology.

Foundational Concept	Advanced Extension
Osmotic laxatives (PEG)	PEG-based bowel preparations (GoLYTELY, MoviPrep) for colonoscopy — high-volume osmotic lavage that completely cleanses the colon; understanding electrolyte-balanced vs. low-volume formulations
Opioid-receptor antimotility agents	PAMORAs (methylnaltrexone, naloxegol, naldemedine) — peripherally acting μ-opioid receptor antagonists for OIC that selectively reverse GI opioid effects without crossing the BBB to reverse analgesia
GC-C agonists (linaclotide)	Visceral pain modulation in IBS-C — linaclotide's extracellular cGMP inhibits nociceptor firing, providing dual secretory and analgesic benefit; investigational GC-C agonists for other functional GI disorders
Lactulose as osmotic laxative	Hepatic encephalopathy management — lactulose lowers colonic pH to convert ammonia (NH₃) to ammonium (NH₄⁺), trapping it in the lumen for fecal excretion; rifaximin adjunct therapy
Serotonin and enteric motility	5-HT₄ agonists (prucalopride) for chronic constipation; 5-HT₃ antagonists (alosetron) for IBS-D — leveraging the enteric serotonergic system to modulate motility and secretion

How foundational GI pharmacology connects to advanced therapeutic agents

The evolution from empirical cathartics to targeted molecular therapies reflects the broader trajectory of pharmacology as a discipline. As our understanding of enteric neuroscience, ion channel physiology, and the gut microbiome deepens, expect even more precise therapeutic tools—such as microbiome-modulating agents, engineered probiotics, and fecal microbiota transplantation (FMT)—to augment or replace conventional laxatives and antidiarrheals in select clinical contexts. Students who master the mechanistic foundations presented here will be well positioned to evaluate and integrate these emerging therapies into evidence-based practice.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why bulk-forming laxatives like psyllium can paradoxically worsen constipation—or even cause bowel obstruction—if a patient does not consume adequate fluids. What is the underlying pharmacological principle?

Show answer

Bulk-forming laxatives are hydrophilic polymers that require water to swell and form a gel-like mass. Without sufficient luminal water, the unhydrated fiber increases fecal bulk without softening, creating a dry, dense bolus that can become impacted in the colon. The pharmacological principle is that the mechanism of action (water absorption to increase fecal mass and trigger stretch-receptor-mediated peristalsis) depends on the availability of an adequate aqueous environment. This is analogous to a sponge placed in a dry container—it cannot expand or function as intended without water. Patients should be counseled to drink at least 240 mL (8 oz) of water with each dose.

Question 2: BASIC CALCULATION

A patient with constipation is started on PEG 3350 at a dose of 17 g dissolved in 240 mL of water once daily. The PEG 3350 powder comes in a 510 g bottle. How many days will one bottle last, and how many liters of total solution will the patient consume from PEG preparations over this period?

Show answer

One bottle contains 510 g of PEG 3350. At a daily dose of 17 g, the number of days the bottle will last is: 510 g ÷ 17 g/day = 30 days. Each dose requires 240 mL of water, so over 30 days the total volume consumed is 240 mL × 30 = 7,200 mL = 7.2 liters. This calculation is clinically relevant because PEG 3350 retains this water isosmotically in the lumen—the fluid volume contributes meaningfully to the osmotic laxative effect. Patients should be reminded that this 240 mL per dose is the minimum mixing volume; additional daily fluid intake is still necessary for general hydration.

Question 3: INTERMEDIATE

A 45-year-old patient with HIV on antiretroviral therapy presents with chronic watery diarrhea. Stool studies are negative for infectious etiologies. The physician is considering crofelemer. Explain the mechanism by which crofelemer reduces diarrhea, and contrast this with the mechanism of loperamide. Why might crofelemer be preferred in this specific clinical context?

Show answer

Crofelemer is an antisecretory agent that inhibits two chloride channels on the luminal (apical) membrane of intestinal epithelial cells: the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC). By blocking chloride efflux into the lumen, it reduces the osmotic driving force for water secretion, thereby decreasing stool water content and volume. In contrast, loperamide is a μ-opioid receptor agonist that slows intestinal transit by reducing propulsive peristalsis and increasing segmental contractions, without directly affecting secretion. Crofelemer is preferred in HIV-associated diarrhea because it targets the secretory component without impeding the transit of potential pathogens, and it acts luminally with minimal systemic absorption, reducing drug–drug interactions with antiretroviral medications. Loperamide, while effective symptomatically, could mask ongoing secretory pathology and carries a theoretical concern for delayed pathogen clearance.

Question 4: APPLIED

A 72-year-old male with heart failure (EF 30%), CKD stage 4 (eGFR 22 mL/min), and chronic opioid use for cancer pain presents with severe constipation unresponsive to docusate sodium monotherapy. Which laxative classes would you avoid and why? Develop a step-up treatment plan with at least three therapeutic tiers.

Show answer

In this complex patient, several laxative classes carry significant risk. Magnesium-based osmotic agents (Mg(OH)₂, magnesium citrate) are contraindicated due to CKD stage 4—impaired renal excretion can cause life-threatening hypermagnesemia. Sodium phosphate preparations risk hyperphosphatemia and acute kidney injury. Large-volume PEG bowel preparations should be used cautiously given fluid overload risk in heart failure. A rational step-up plan: Tier 1 — Discontinue docusate monotherapy (limited evidence for efficacy); start PEG 3350 at 17 g/day in the minimum mixing volume (240 mL) and add a bulk-forming agent (psyllium) if the patient can tolerate adequate fluid. Tier 2 — If inadequate response in 48–72 hours, add an intermittent stimulant laxative (bisacodyl suppository 10 mg PRN) to provide direct colonic stimulation. Tier 3 — Given opioid-induced constipation, escalate to a peripherally acting μ-opioid receptor antagonist (PAMORA) such as subcutaneous methylnaltrexone (which is renally dose-adjusted but usable in CKD) to directly reverse the peripheral opioid effect without compromising pain control. Throughout, monitor serum electrolytes (K⁺, Mg²⁺, PO₄³⁻) and fluid balance closely.

Question 5: CRITICAL THINKING

Linaclotide, a GC-C agonist, is approved for both chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Critically analyze why a single drug can treat two conditions with different pathophysiologies. Discuss the dual mechanism of linaclotide—its prosecretory and visceral analgesic effects—and evaluate whether this represents a true mechanistic advantage or simply a broadening of indications based on overlapping symptoms.

Show answer

Linaclotide's dual indication is pharmacologically justified rather than merely a marketing extension. In CIC, the primary problem is insufficient luminal fluid and sluggish transit; linaclotide addresses this by activating GC-C receptors on the apical surface of enterocytes, increasing intracellular cGMP, which activates CFTR chloride channels and inhibits NHE3 sodium absorption. The net effect is chloride and water secretion into the lumen, softening stool and accelerating transit. In IBS-C, patients share the constipation phenotype but also experience visceral hypersensitivity (abdominal pain and bloating). Linaclotide addresses this through a second, distinct mechanism: extracellular cGMP released from enterocytes into the submucosal space inhibits afferent nociceptor firing, reducing visceral pain signaling. This analgesic effect is independent of the secretory action and is mediated by cGMP acting on pain-sensing neurons in the colonic mucosa. This represents a genuine mechanistic advantage—not merely symptom overlap—because the drug simultaneously targets two pathophysiological axes (secretion and sensation) through a single receptor system. However, a critical limitation is that the analgesic effect may not be sufficient for patients with severe visceral pain, and the drug does not address the central sensitization component of IBS. Additionally, the most common adverse effect—diarrhea—can limit tolerability, particularly in CIC patients who may be less tolerant of loose stools than IBS-C patients are. The dual mechanism is a real pharmacological innovation, but it does not make linaclotide a panacea for all functional bowel disorders.

SUMMARY

Lesson Summary

Summary

Laxatives and antidiarrheals comprise pharmacologically diverse drug classes that converge on regulating intestinal fluid balance and motility. Laxatives include bulk-forming agents (psyllium, methylcellulose) that increase fecal mass, osmotic agents (PEG 3350, lactulose, magnesium salts) that draw water into the lumen, stimulant agents (bisacodyl, senna) that activate the myenteric plexus, stool softeners (docusate) that act as surfactants, and prosecretory agents (lubiprostone, linaclotide) that activate chloride channels or GC-C receptors to increase intestinal secretion.

Antidiarrheals include opioid-receptor agonists (loperamide, diphenoxylate/atropine) that reduce peristalsis via μ-receptor activation, adsorbents (bismuth subsalicylate) that coat mucosa and reduce secretion, and antisecretory agents (crofelemer) that block luminal chloride channels. Rational drug selection requires matching the agent's mechanism to the underlying pathophysiology—considering patient comorbidities (renal function, cardiac status), concurrent medications (opioids, antiretrovirals), and contraindications (bloody diarrhea, bowel obstruction). This mechanism–etiology match principle is the cornerstone of evidence-based GI pharmacotherapy.